<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30012595</article-id>
<article-id pub-id-type="pmc">6077728</article-id>
<article-id pub-id-type="publisher-id">201803792</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1803792115</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Medical Sciences</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacological reactivation of inactive X-linked <italic>Mecp2</italic> in cerebral cortical neurons of living mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Przanowski</surname>
<given-names>Piotr</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wasko</surname>
<given-names>Urszula</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Zeming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sherman</surname>
<given-names>Robyn</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Lihua Julie</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McConnell</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tushir-Singh</surname>
<given-names>Jogender</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-3017-3298</contrib-id>
<name>
<surname>Green</surname>
<given-names>Michael R.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhatnagar</surname>
<given-names>Sanchita</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Department of Biochemistry and Molecular Genetics, <institution>University of Virginia School of Medicine</institution>, Charlottesville, <addr-line>VA</addr-line> 22908;</aff>
<aff id="aff2"><sup>b</sup>Department of Molecular, Cell and Cancer Biology, <institution>University of Massachusetts Medical School</institution>, Worcester, <addr-line>MA</addr-line> 01605;</aff>
<aff id="aff3"><sup>c</sup>Programs in Molecular Medicine and Bioinformatics and Integrative Biology, <institution>University of Massachusetts Medical School</institution>, Worcester, <addr-line>MA</addr-line> 01605;</aff>
<aff id="aff4"><sup>d</sup>Department of Neuroscience, <institution>University of Virginia School of Medicine</institution>, Charlottesville, <addr-line>VA</addr-line> 22908;</aff>
<aff id="aff5"><sup>e</sup><institution>Howard Hughes Medical Institute</institution>, <institution>University of Massachusetts Medical School</institution>, Worcester, <addr-line>MA</addr-line> 01605</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>sb5fk@virginia.edu</email> or <email>michael.green@umassmed.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Michael R. Green, June 19, 2018 (sent for review March 2, 2018; reviewed by Aseem Z. Ansari and Sukesh R. Bhaumik)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: P.P., U.W., M.J.M., J.T.-S., and S.B. designed research; P.P., U.W., Z.Z., R.S., and S.B. performed research; M.R.G. contributed new reagents/analytic tools; P.P., J.Y., L.J.Z., J.T.-S., and S.B. analyzed data; and P.P., M.R.G., and S.B. wrote the paper.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: A.Z.A., University of Wisconsin-Madison; and S.R.B., Southern Illinois University School of Medicine.</p>
</fn>
<fn fn-type="COI-statement">
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>31</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>115</volume>
<issue>31</issue>
<fpage>7991</fpage>
<lpage>7996</lpage>
<permissions>
<copyright-year>2018</copyright-year>
<license>
<ali:license_ref specific-use="vor" xmlns:ali="http://www.niso.org/schemas/ali/1.0/"></ali:license_ref>
<license-p>Published under the <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/site/aboutpnas/licenses.xhtml">PNAS license</ext-link>.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201803792.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Rett syndrome (RTT) is a devastating neurodevelopmental disorder with no cure. RTT typically affects females and is caused by mutations in one of the two copies of the X-linked gene <italic>MECP2</italic>. Due to X chromosome inactivation, the random silencing of one X chromosome, females with RTT have a mixture of cells that express either normal or mutant <italic>MECP2</italic>. Importantly, cells expressing mutant <italic>MECP2</italic> retain a normal copy of <italic>MECP2</italic> on the inactive X chromosome (Xi), the reactivation of which represents a potential therapeutic approach for RTT. Here we use small-molecule inhibitors to reactivate the Xi-linked <italic>Mecp2</italic> gene in brain neurons of living mice. Our results further establish the feasibility of Xi-linked <italic>MECP2</italic> reactivation-based therapeutics for treatment of RTT.</p>
</abstract>
<abstract>
<p>Rett syndrome (RTT) is a genetic disorder resulting from a loss-of-function mutation in one copy of the X-linked gene methyl-CpG–binding protein 2 (<italic>MECP2</italic>). Typical RTT patients are females and, due to random X chromosome inactivation (XCI), ∼50% of cells express mutant MECP2 and the other ∼50% express wild-type MECP2. Cells expressing mutant MECP2 retain a wild-type copy of MECP2 on the inactive X chromosome (Xi), the reactivation of which represents a potential therapeutic approach for RTT. Previous studies have demonstrated reactivation of Xi-linked <italic>MECP2</italic> in cultured cells by biological or pharmacological inhibition of factors that promote XCI (called “XCI factors” or “XCIFs”). Whether XCIF inhibitors in living animals can reactivate Xi-linked <italic>MECP2</italic> in cerebral cortical neurons, the cell type most therapeutically relevant to RTT, remains to be determined. Here, we show that pharmacological inhibitors targeting XCIFs in the PI3K/AKT and bone morphogenetic protein signaling pathways reactivate Xi-linked <italic>MECP2</italic> in cultured mouse fibroblasts and human induced pluripotent stem cell-derived postmitotic RTT neurons. Notably, reactivation of Xi-linked <italic>MECP2</italic> corrects characteristic defects of human RTT neurons including reduced soma size and branch points. Most importantly, we show that intracerebroventricular injection of the XCIF inhibitors reactivates Xi-linked <italic>Mecp2</italic> in cerebral cortical neurons of adult living mice. In support of these pharmacological results, we also demonstrate genetic reactivation of Xi-linked <italic>Mecp2</italic> in cerebral cortical neurons of living mice bearing a homozygous XCIF deletion. Collectively, our results further establish the feasibility of pharmacological reactivation of Xi-linked <italic>MECP2</italic> as a therapeutic approach for RTT.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Mecp2</italic>
</kwd>
<kwd>mouse model</kwd>
<kwd>Rett syndrome</kwd>
<kwd>X chromosome reactivation</kwd>
<kwd>brain neurons</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Hartwell Foundation (The Hartwell Foundation)<named-content content-type="funder-id">100006792</named-content></funding-source>
<award-id rid="sp1">Pending</award-id>
<principal-award-recipient>Sanchita Bhatnagar</principal-award-recipient>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">Howard Hughes Medical Institute (HHMI)<named-content content-type="funder-id">100000011</named-content></funding-source>
<award-id rid="sp2">068101</award-id>
<principal-award-recipient>Michael R. Green</principal-award-recipient>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>